

PUBLIC COPY

RECEIVED
OPPT CBIC

MR# 338363

September 21, 2011

2011 SEP 22 AM 11:41

Via Federal Express

Document Processing Center (Mail Code 7407M)
Room 6428
Attention: 8(e) Coordinator
Office of Pollution Prevention and Toxics
U.S. Environmental Protection Agency
1201 Constitution Ave., NW
Washington, DC 20004



Dear 8(e) Coordinator:

Partially Fluorinated Condensation Polymer and Methacrylic copolymer with surfactant in water

This letter is to inform you of the results of an acute daphnia study with the above referenced test substance. This test mixture contains a substance that is subject to a Consent Order, PMN P-07-0087.

The acute toxicity of the test substance to the cladoceran, *Daphnia magna*, was determined in a static, 48-hour non-GLP screening test. The study was conducted with four nominal concentrations of the test substance and a dilution water control at a temperature of $20 \pm 1^\circ\text{C}$. One test chamber with 10 organisms was used per test substance concentration and the control. Exposure of the test organism to nominal concentrations of 0.12, 1.2, 12, and 120 mg solids/L (equivalent to 0.759, 7.59, 75.9, and 759 mg test substance/L) resulted in 0, 90, 100, and 100% immobility, respectively, at the end of 48-hours. No sublethal effects were observed at the end of the study. No immobility or sublethal effects were observed in the control organisms. The 48-hour EC_{50} , based on nominal concentrations of solids in the test substance and immobility, was 0.379 mg solids/L.

Sincerely,



Company Sanitized

TSCA §8(e) SUBMISSION
SUBSTANTIATION OF CONFIDENTIALITY CLAIM

Substantiation Questions

1. Is your company asserting this confidential business information (CBI) claim on its own behalf?

Yes.

If the answer is no, please provide company name, address and telephone number of entity asserting claim.

2. For what period do you assert your claim(s) of confidentiality? If the claim is to extend until a certain event or point in time, please indicate that event or time period. Explain why such information should remain confidential until such point.

The claim of confidentiality is requested permanently, or until the submitter makes the information common knowledge.

3. Has the information that you are claiming as confidential been disclosed to any other governmental agency, or to this Agency at any other time? Identify the Agency to which the information was disclosed and provide the date and circumstances of the same. Was the disclosure accompanied by a claim of confidentiality? If yes, attach a copy of said document reflecting the confidentiality agreement.

The information claimed as confidential [

]

4. Briefly describe any physical or procedural restrictions within your company relating to the use and storage of the information you are claiming CBI.

Submitter maintains the identity of the confidential substance as proprietary information. Disclosure of the confidential substance identity within the Company is on a need-to-know basis. Employees who do have access to the information are contractually prohibited from unauthorized disclosure of such information. Materials are referred to by a generic name or product code.

5. If anyone outside your company has access to any of the information claimed CBI, are they restricted by confidentiality agreement(s). If so, explain the content of the agreement(s).

[

], no one outside the company has access to the information claimed under the CBI.

6. Does the information claimed as confidential appear or is it referred to in any of the following:

a. Advertising or promotional material for the chemical substance or the resulting and product;

No.

b. Material safety data sheets or other similar materials (such as technical data sheets) for the substance or resulting end product (include copies of this information as it appears when

accompanying the substance and/or product at the time of transfer or sale);

No.

c. Professional or trade publications;

No.

d. Any other media or publications available to the public or to your competitors.

No.

If you answered yes to any of the above, indicate where the information appears, include copies, and explain why it should nonetheless be treated as confidential.

7. Has EPA, another federal agency, or court made any confidentiality determination regarding information associated with this substance? If so, provide copies of such determinations.

No.

8. Describe the substantial harmful effects that would result to your competitive position if the CBI information is made available to the public? In your answer, explain the causal relationship between disclosure and any resulting substantial harmful effects. Consider in your answer such constraints as capital and marketing cost, specialized technical expertise, or unusual processes and your competitors access to your customers. Address each piece of information claimed CBI separately.

Disclosure of the claimed CBI would result in harmful effects on submitter's competitive position since the submitter has committed, or expects to commit, a significant amount of time, resources, and dollars to the research and development of the test substance. Disclosure of the claimed CBI would permit a competitor to specifically know and understand the submitter's research efforts with this test substance and to forego the necessary time and expense to develop and test such a substance, thus capitalizing on the submitter's research and development efforts. This knowledge could be used by competitors to introduce new patents and/or competitive products in the areas of interest to our company which would otherwise reduce the value of this product for our business.

9. Has the substance been patented in the U.S. or elsewhere? Is a patent for the substance currently pending?

[

]

10. Is this substance/product commercially available and if so, for how long has it been available on the commercial market?

Yes. []

- a. If on the commercial market, are your competitors aware that the substance is commercially available in the U.S.?

Yes.

b. If not already commercially available, describe what stage of research and development (R&D) the substance is in, and estimate how soon a market will be established.

N/A

c. What is the substance used for and what type of product(s) does it appear in.

The substance is used [
]

11. Describe whether a competitor could employ reverse engineering to identically recreate the substance?

It is anticipated that a competitor could readily reverse engineer this product, especially if CBI is revealed.

12. Do you assert that disclosure of this information you are claiming CBI would reveal:

a. Confidential processes used in manufacturing the substance;

Yes.

b. If a mixture, the actual portions of the substance in the mixture; or

Yes.

c. Information unrelated to the effects of the substance on human health or the environment?

Yes.

If your answer to any of the above questions is yes, explain how such information would be revealed.

It would be a simple matter for competitors, having gained knowledge of [
]

], thereby limiting potential competitive advantage.

13. Provide the Chemical Abstract Service Registry Number for the product, if known. Is your company applying for a CAS number now or in the near future? If you have applied for a CAS number, include a copy of the contract with CAS.

[
]

]

14. Is the substance or any information claimed CBI the subject of FIFRA regulation or reporting? If so, explain.

No.